Clinical observation of quadruple therapy combined with Saccharomyces boulardii powder and Jinghua Weikang Capsule in the treatment of Helicobacter pylori positive chronic gastritis
-
摘要: 目的：探讨四联疗法联合布拉氏酵母菌散、荆花胃康胶丸治疗Hp阳性慢性胃炎的临床效果。方法：选取2020年4月-9月就诊的Hp阳性慢性胃炎患者180例，依随机数字表法分为2组，每组各90例。对照组行四联疗法（奥美拉唑+阿莫西林+呋喃唑酮+枸橼酸铋钾）治疗2周；观察组在四联疗法的基础上服用布拉氏酵母菌散、荆花胃康胶丸，疗程2周。比较2组临床疗效、Hp根除率及不良反应发生率。结果：观察组的疗效（总有效率为94.44%，Hp根除率为92.22%）明显高于对照组（总有效率为83.33%，Hp根除率为81.11%），均差异有统计学意义（P<0.05）；治疗2周后，2组胃痛、口苦口干、嗳气反酸、胃脘胀满症状积分均下降，且观察组低于对照组（P<0.05）；治疗期间，观察组不良反应发生率明显低于对照组（P<0.05）。结论：四联方案+布拉氏酵母菌散、荆花胃康胶丸用于Hp阳性慢性胃炎患者的治疗中具有良好的临床疗效，可提高Hp的根除率，且临床症状改善优于四联疗法，用药安全性较好。Abstract: Objective: To investigate the clinical effect of quadruple therapy combined with Saccharomyces boulardii powder and Jinghua Weikang Capsule in the treatment of Helicobacter pylori(Hp) positive chronic gastritis. Methods: According to the random number table method, 180 cases of Hp positive chronic gastritis patients from April 2020 to September 2020 were randomly divided into two groups. The control group(90 cases) was treated with quadruple therapy(omeprazole+amoxicillin+furazolidone+bismuth potassium citrate) for 2 weeks, and the observation group(90 cases) was given Saccharomyces boulardii powder and Vitex trifolia on the basis of quadruple therapy Jinghua Weikang Capsule was given for 2 weeks. The clinical efficacy, Hp eradication rate and incidence of adverse reactions were compared between the two groups. Results: The total effective rate of the observation group(total effective rate 94.44%, Hp eradication rate 92.22%) was significantly higher than that of the control group(total effective rate 83.33%, Hp eradication rate 81.11%), after 2 weeks of treatment, the symptom scores of stomachache, epigastric fullness, belching and acid regurgitation, bitter mouth and dry mouth symptoms in the two groups were decreased, and the observation group was lower than the control group(P<0.05); The incidence of adverse reactions in the observation group was significantly lower than that in the control group(P<0.05). Conclusion: Quadruple regimen plus Saccharomyces boulardii powder and Jinghua Weikang Capsule have good clinical efficacy in patients with Hp positive chronic gastritis, and can improve the eradication rate of Hp, and the improvement of clinical symptoms is better than quadruple therapy, and the medication safety is better.
-
-
[1] Zamani M, Ebrahimtabar F, Zamani V, et al.Systematic review with meta-analysis:the worldwide prevalence of Helicobacter pylori infection[J].Aliment Pharm Ther, 2018, 47(7):868-876.
[2] Yamada S, Tomatsuri N, Kawakami T, et al.Helicobacter pylori Eradication Therapy Ameliorates Latent Digestive Symptoms in Chronic Atrophic Gastritis[J].Digestion, 2018, 97(4):333-335.
[3] 中华医学会消化病学分会幽门螺杆菌和消化性溃疡学组全国幽门螺杆菌研究协作组.第五次全国幽门螺杆菌感染处理共识报告[J].中华消化杂志, 2017, 37(6):364-378.
[4] 世界中医药学会联合会消化病专业委员会.痞满中医临床实践指南(2018)[J].中医杂志, 2019, 60(17):1520-1529.
[5] 公凡杰, 王伟明, 孙荣娟, 等.小建中胶囊联合三联疗法抗幽门螺旋杆菌的临床疗效观察[J].中国中西医结合消化杂志, 2018, 26(5):454-456.
[6] 刘文忠, 谢勇, 陆红, 等.第五次全国幽门螺杆菌感染处理共识报告[J].胃肠病学, 2017, 22(6):346-360.
[7] 张声生, 唐旭东, 黄穗平, 等.慢性胃炎中医诊疗专家共识意见(2017)[J].中华中医药杂志, 2017, 32(7):3060-3064.
[8] Malfertheiner P, Megraud F, O'Morain CA.Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report[J].Gut, 2017, 66(1):6-30.
[9] Chey WD, Leontiadis GI, Howden CW, et al.ACG Clinical Guideline:Treatment of Helicobacter pylori Infection[J].Am J Gastroenterol, 2017, 112(2):212-239.
[10] Smith S, Boyle B, Brennan D, et al.The Irish Helicobacter pylori Working Group consensus for the diagnosis and treatment of H.pylori infection in adult patients in Ireland[J].Eur J Gastroen Hepat, 2017, 29(5):552-559.
[11] 中华医学会消化病学分会幽门螺杆菌和消化性溃疡学组全国幽门螺杆菌研究协作组.第五次全国幽门螺杆菌感染处理共识报告[J].中华内科杂志, 2017, 56(7):532-545.
[12] Flores-Trevio S, Mendoza-Olazarán S, Bocanegra-Ibarias P, et al.Helicobacter pylori drug resistance:therapy changes and challenges[J].Expert Rev Gastroent, 2018, 12(8):819-827.
[13] 杨琼, 尚琪, 魏国强, 等, 含祕剂四联方案联合荆花胃康胶丸治疗幽门螺杆菌感染的前瞻性多中心随机对照研究[J].中华医学杂志, 2019, 99(4):295-299.
[14] 张学智, 魏玮, 蓝宇.成人幽门螺杆菌引起的胃炎中西医协作诊疗专家共识(2020, 北京)[J].中医杂志, 2020, 61(22):2016-2024.
[15] 暴梅佳.中医药防治幽门螺旋杆菌研究进展[J].食品与药品, 2017, 19(1):71-75.
[16] 李蓉蓉.布拉氏酵母菌散, 荆花胃康胶丸联合标准四联疗法根治幽门螺杆菌感染的临床研究[D].太原:山西中医药大学, 2019.
[17] 李建勋, 吕宾, 杜勤, 等.荆花胃康胶丸联合铋剂四联治疗幽门螺杆菌阳性慢性胃炎多中心随机对照研究[J].中国中西医结合消化杂志, 2018, 26(12):998-1004.
[18] 于靖, 张学智, 史宗明, 等.土荆芥挥发油对幽门螺杆菌甲硝唑耐药株及敏感株的体外抗菌作用研究[J].北京中医药, 2018, 37(10):929-931.
[19] 杨佳卉, 梁雨, 罗培培, 等.荆花胃康联合三联或四联疗法与四联疗法对比治疗幽门螺旋杆菌相关慢性胃炎或消化性溃疡有效性和安全性的Meta分析[J].中国全科医学, 2019, 22(17):2091-2011.
[20] 姜欣, 刘丹, 韩林, 等.荆花胃康胶丸联合四联疗法治疗Hp阳性老年慢性胃炎的临床效果[J].中国医药导报, 2020, 17(18):155-158.
[21] 姚国鹏, 李启祥, 段雪辉, 等.荆花胃康胶丸联用四联疗法补救治疗幽门螺杆菌感染的随机对照研究[J].现代消化及介入诊疗, 2020, 25(7):922-925.
[22] Asmat S, Shaukat F, Asmat R, et al.Clinical Efficacy Comparison of Saccharomyces Boulardii and Lactic Acid as Probiotics in Acute Pediatric Diarrhea[J].J Coll Physicians Surg Pak, 2018, 28(3):214-217.
[23] Priscilla FC, Justino AX, Franco RP, et al.Modulation of 5-fluorouracil activation of toll-like/MyD88/NF-κB/MAPK pathway by Saccharomyces boulardii CNCM I-745 probiotic[J].Cytokine, 2019, 12(25):1084-1097.
[24] 刘辉.布拉氏酵母菌散与乳果糖联合治疗小儿功能性便秘效果分析[J].北方药学, 2019, 16(10):23-25.
[25] 贺金娥, 王微, 高春燕.布拉氏酵母菌散剂联合三联疗法对儿童幽门螺杆菌感染的治疗[J].中国微生态学杂志, 2019, 31(2):171-178.
[26] 何晨熙, 孔凡庭, 梁芳王, 等.不同时机加用布拉氏酵母菌联合四联疗法根除幽门螺杆菌的疗效分析[J].中华医学杂志, 2019, 99(22):1731-1733.
-
计量
- 文章访问数: 253
- PDF下载数: 268
- 施引文献: 0
下载: